Cargando…

Time-resolved trajectory of glucose lowering medications and cardiovascular outcomes in type 2 diabetes: a recurrent neural network analysis

AIM: Treatment algorithms define lines of glucose lowering medications (GLM) for the management of type 2 diabetes (T2D), but whether therapeutic trajectories are associated with major adverse cardiovascular events (MACE) is unclear. We explored whether the temporal resolution of GLM usage discrimin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Longato, Enrico, Di Camillo, Barbara, Sparacino, Giovanni, Avogaro, Angelo, Fadini, Gian Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396779/ https://www.ncbi.nlm.nih.gov/pubmed/35996111 http://dx.doi.org/10.1186/s12933-022-01600-x

Ejemplares similares

Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
por: Longato, Enrico, et al.
Publicado: (2020)

Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice
por: Longato, Enrico, et al.
Publicado: (2020)

Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study
por: Longato, Enrico, et al.
Publicado: (2021)

Management of type 2 diabetes with a treat-to-benefit approach improved long-term cardiovascular outcomes under routine care
por: Morieri, Mario Luca, et al.
Publicado: (2022)

Improved long-term cardiovascular outcomes after intensive versus standard screening of diabetic complications: an observational study
por: Morieri, Mario Luca, et al.
Publicado: (2019)

Deep-learning-based natural-language-processing models to identify cardiovascular disease hospitalisations of patients with diabetes from routine visits’ text
por: Guazzo, Alessandro, et al.
Publicado: (2023)

Time-series analysis of multidimensional clinical-laboratory data by dynamic Bayesian networks reveals trajectories of COVID-19 outcomes
por: Longato, Enrico, et al.
Publicado: (2022)

Performance assessment across different care settings of a heart failure hospitalisation risk-score for type 2 diabetes using administrative claims
por: Guazzo, Alessandro, et al.
Publicado: (2022)

Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics
por: Morieri, Mario Luca, et al.
Publicado: (2020)

Assessment of Glucose Lowering Medications’ Effectiveness for Cardiovascular Clinical Risk Management of Real-World Patients with Type 2 Diabetes: Targeted Maximum Likelihood Estimation under Model Misspecification and Missing Outcomes
por: Sciannameo, Veronica, et al.
Publicado: (2022)

Challenges and opportunities in real‐world evidence on the renal effects of sodium‐glucose cotransporter‐2 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2021)

It Is All in the Blood: The Multifaceted Contribution of Circulating Progenitor Cells in Diabetic Complications
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

How to interpret the role of SDF-1α on diabetic complications during therapy with DPP-4 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice
por: Avogaro, Angelo, et al.
Publicado: (2016)

Amelioration of Glucose Control Mobilizes Circulating Pericyte Progenitor Cells in Type 2 Diabetic Patients with Microangiopathy
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

Effectiveness of adding alarms to flash glucose monitoring in adults with type 1 diabetes under routine care
por: Boscari, Federico, et al.
Publicado: (2022)

Changes in the Prescription of Glucose‐Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study
por: Fadini, Gian Paolo, et al.
Publicado: (2019)

Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Managing diabetes in diabetic patients with COVID: where do we start from?
por: Avogaro, Angelo, et al.
Publicado: (2021)

Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice
por: Morieri, Mario Luca, et al.
Publicado: (2020)

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
por: Bonora, Benedetta Maria, et al.
Publicado: (2020)

Response to Chia Siang Kow and colleagues
por: Avogaro, Angelo, et al.
Publicado: (2022)

Prevalence and impact of diabetes among people infected with SARS-CoV-2
por: Fadini, G. P., et al.
Publicado: (2020)

Infection Rates and Impact of Glucose Lowering Medications on the Clinical Course of COVID-19 in People with Type 2 Diabetes: A Retrospective Observational Study
por: Mannucci, Francesca, et al.
Publicado: (2022)

Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection
por: Avogaro, Angelo, et al.
Publicado: (2014)

SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
por: Bonora, Benedetta Maria, et al.
Publicado: (2021)

The Endothelium Abridges Insulin Resistance to Premature Aging
por: Avogaro, Angelo, et al.
Publicado: (2013)

Endothelial Dysfunction in Diabetes: The role of reparatory mechanisms
por: Avogaro, Angelo, et al.
Publicado: (2011)

Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial
por: Bonora, Benedetta Maria, et al.
Publicado: (2019)

Glycaemic Control Among People with Type 1 Diabetes During Lockdown for the SARS-CoV-2 Outbreak in Italy
por: Bonora, Benedetta Maria, et al.
Publicado: (2020)

Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2019)

The dipeptidyl peptidase-4 inhibitor Saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients
por: Poncina, Nicol, et al.
Publicado: (2014)

DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes
por: Fadini, Gian Paolo, et al.
Publicado: (2017)

Mitochondrial Calcium Uptake Is Instrumental to Alternative Macrophage Polarization and Phagocytic Activity
por: Tedesco, Serena, et al.
Publicado: (2019)

Improved prediction of long-term kidney outcomes in people with type 2 diabetes by levels of circulating haematopoietic stem/progenitor cells
por: Bonora, Benedetta Maria, et al.
Publicado: (2023)

Effectiveness of remote screening for diabetic retinopathy among patients referred to Mozambican Diabetes Association (AMODIA): a retrospective observational study
por: Rigato, Mauro, et al.
Publicado: (2022)

Clinical Features, Cardiovascular Risk Profile, and Therapeutic Trajectories of Patients with Type 2 Diabetes Candidate for Oral Semaglutide Therapy in the Italian Specialist Care
por: Morieri, Mario Luca, et al.
Publicado: (2023)

p66Shc gene expression in peripheral blood mononuclear cells and progression of diabetic complications
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes
por: Sciannameo, V., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mj915i8fo41vlues58n0dgeiao